VU 0357121 CAS:433967-28-3

CAS NO: 433967-28-3
VU 0357121 CAS:433967-28-3
Description Review

VU0357121, also known as VU-0357121, is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor subtype 4 (mGluR4). This product has been of interest to researchers in recent years due to its potential therapeutic benefits, particularly as a treatment for Parkinson's disease. In this article, we will explore some of the key information regarding VU0357121, including its chemical composition, health benefits, potential effects, mechanisms of action, safety considerations, dosing information, and more.

Chemical Name, Molecular Formula, Formula Weight, and CAS No

The chemical name of VU0357121 is N-(3-chloro-4-fluorophenethyl)-N'-(propylsulfonyl) urea. Its molecular formula is C15H20ClFN2O3S, and its formula weight is 372.85 g/mol. The CAS number for VU0357121 is 433967-28-3.

Top Ten Keywords and Synonyms

Some of the top ten keywords associated with VU0357121 include "mGluR4," "Parkinson's disease," "positive allosteric modulator," "neuroprotective," "pharmacology," "dopaminergic neurons," "synaptic transmission," "glutamatergic system," "neurodegeneration," and "brain disorders." Synonyms for VU0357121 include "N-(3-Chloro-4-fluorophenethyl)-N'-propylsulfonylurea" and "VU-0357121."

Health Benefits

Researchers have explored the potential health benefits of VU0357121 in a range of contexts, but most of the focus has been on its ability to protect dopaminergic neurons in the brain, which are involved in movement control and are often damaged in Parkinson's disease. Studies suggest that mGluR4 activation can reduce inflammation and oxidative stress, two key drivers of neurodegeneration. VU0357121 has shown promise in preclinical studies as a neuroprotective agent that could slow or even halt the progression of Parkinson's disease.

Potential Effects

The effects of VU0357121 are primarily related to its impact on the glutamatergic system in the brain. By binding to the mGluR4 receptor, VU0357121 enhances the activity of this receptor, leading to increased dopamine release and improved synaptic transmission. This, in turn, can improve movement control and reduce the symptoms of Parkinson's disease. Additionally, VU0357121 may have broader neuroprotective effects that could be relevant for other brain disorders.

Product Mechanism

VU0357121 acts as a positive allosteric modulator of the mGluR4 receptor, meaning that it enhances the activity of this receptor without directly stimulating it. Specifically, VU0357121 binds to an allosteric site on the mGluR4 receptor, which leads to a conformational change that enhances the receptor's response to glutamate. This increases the release of dopamine from dopaminergic neurons, which improves movement control and reduces the symptoms of Parkinson's disease.


While there is still much to learn about the safety profile of VU0357121, early preclinical studies suggest that it is generally well-tolerated and has few side effects. However, further research is needed to determine whether there are any long-term safety concerns associated with this product, particularly if it were to be used in humans over an extended period of time.

Side Effects

To date, few side effects have been reported in preclinical studies of VU0357121. However, as with any new drug, there is always the possibility of unexpected adverse effects emerging in the future. Some potential side effects that have been suggested based on the mechanism of action of VU0357121 include changes in blood pressure, heart rate, and body temperature, although these effects have not yet been observed in studies of the product.

Dosing Information

The optimal dosing regimen for VU0357121 in humans has not yet been established, as the majority of studies have been conducted in animal models. However, based on preclinical data, it is likely that a relatively low dose of VU0357121 would be effective in treating Parkinson's disease while minimizing the risk of side effects. Further research is needed to determine the optimal dosing and administration schedule for this product.


VU0357121 is a promising new product that has attracted significant attention from researchers studying Parkinson's disease and other brain disorders. As a positive allosteric modulator of the mGluR4 receptor, VU0357121 has the potential to protect dopamine-producing neurons and improve movement control in patients with Parkinson's disease. While more research is needed to fully understand


Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe